Is FibroGen, Inc. (FGEN) a Buy, Sell, or Hold?
NASDAQ : FGEN
FibroGen, Inc.
$9.07 USD
-$0.15 (-1.63%)
- Volume
- 29.26K
- Average Volume
- 33.23K
- Market Capitalization
- $36.69M
- P/E Ratio
- 0.22
- Dividend Yield
- 0.00%
- Price Target
- $28.00
- Year High
- $21.95
- Year Low
- $4.85
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.61
Company Overview
NASDAQ
Thane Wettig
Biotechnology
Healthcare
FGEN
225
US
USD
Liquidity Metrics
0.00
3.61
3.48
1.32
0.00
Sales & Valuation
$6.44M
4.93
-3.95
-1.71
-5.29
Profitability
$45.37
$183.45M
2199.72%
-761.79%
-267.30%
149.24%
P/E Metrics
0.22
0.00
0.00
Analyst Price Target & Rating
$28.00
$28.00
$28.00
0/5
14 Analysts
-67.61%
Financial Health Scores
-21.89
6/9
$73.24M
$109.63M
$118.92M
-$32.14M
Key Metrics (TTM)
-$304.81K
-0.04
0.01
3.61
-267.30%
-54.95%
445.74%
-58.33%
774 days
Company Executives
| Name | Title |
|---|---|
| John Alden | Corporate Secretary & General Counsel |
| Thane Wettig | Chief Executive Officer & Director |
| David DeLucia | Senior Vice President & Chief Financial Officer |
| Gaia Vasiliver-Shamis | Director of IR & Communications - LifeSci Advisors |
Poll Results
No votes yet today — be the first to share your view!
About FibroGen, Inc. (NASDAQ:FGEN) Stock
FibroGen, Inc. is a biopharmaceutical firm dedicated to discovering, developing, and bringing to market therapies that address significant medical conditions currently lacking effective treatments. Among its pipeline, FibroGen is advancing Roxadustat, an orally administered small molecule that inhibits hypoxia inducible factor prolyl hydroxylases. This drug has successfully completed Phase III clinical trials in the US, Europe, China, and Japan for treating anemia in chronic kidney disease, and is currently in Phase II/III development in China for anemia linked to myelodysplastic syndromes. Additionally, the company is progressing Pamrevlumab, a human monoclonal antibody designed to block connective tissue growth factor. Pamrevlumab is undergoing Phase III clinical development for multiple ... conditions including idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, with a separate Phase III trial also underway for Duchenne muscular dystrophy. FibroGen maintains strategic collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. Established in 1993, FibroGen, Inc. operates from its headquarters in San Francisco, California.
Frequently Asked Questions
-
What is the current FibroGen, Inc. (FGEN) stock price?
-
FibroGen, Inc.(NASDAQ:FGEN) stock price is $9.07 in the last trading session. During the trading session, FGEN stock reached the peak price of $21.95 while $4.85 was the lowest point it dropped to. The percentage change in FGEN stock occurred in the recent session was --1.63% while the dollar amount for the price change in FGEN stock was -$0.15.
-
FGEN's industry and sector of operation?
-
The NASDAQ listed FGEN is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of FGEN?
-
John Alden | Corporate Secretary & General Counsel
Thane Wettig | Chief Executive Officer & Director
David DeLucia | Senior Vice President & Chief Financial Officer
Gaia Vasiliver-Shamis | Director of IR & Communications - LifeSci Advisors
| -
How many employees does FGEN have?
-
Number of FGEN employees currently stands at 225. FGEN operates from 409 Illinois Street, San Francisco, CA 94158, US.
-
Link for FGEN official website?
-
Official Website of FGEN is: https://www.kyntrabio.com
-
How do I contact FGEN?
-
FGEN could be contacted at phone #415 978 1200 and can also be accessed through its website. FGEN operates from 409 Illinois Street, San Francisco, CA 94158, US.
-
How many shares of FGEN are traded daily?
-
The average number of FGEN shares traded daily for last 3 months was 33.23K.
-
What is the market cap of FGEN currently?
-
The market value of FGEN currently stands at $36.69M with its latest stock price at $9.07